Home World News No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced,... World News No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation By Ogkologos - August 24, 2026 127 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SKYSCRAPER-03 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib June 18, 2025 Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen... July 29, 2022 Opinion: ‘We’re making headway, but we can’t be complacent’ February 11, 2021 Load more HOT NEWS Three Brothers Under The Age Of 6 Are All Fighting The... EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for... Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment
